Minerva Neurosciences, Inc. (NERV)
Nasdaq · Healthcare · Biotechnology
$3.32+1.22%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $159M
- 52-week range
- $2.08 – $12.46
- 52-week change
- +53.27%
- EPS (trailing)
- −$36.12
Fiscal year to Dec 2025
- Net income
- −$293M
- Diluted EPS
- −$34.67
From the company’s annual report on SEC EDGAR.
About Minerva Neurosciences, Inc.
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
Headquarters: Burlington, United States · 7 employees · minervaneurosciences.com